LH-receptor agonist glycoprotein
Chorionic gonadotropin (hCG)
Binds LH/hCG receptors, stimulating Leydig-cell testosterone production and maintaining corpus luteum progesterone in labelled uses.
Primary Mechanism of Action
Clinical / Scientific
hCG is a glycoprotein hormone activating the LHCGR. In men this drives testicular steroidogenesis; in women it mimics the LH surge / supports luteal progesterone. Urinary or recombinant pharmaceutical hCG is established; catalog vials must not be confused with a specific licensed presentation.
Pathway Targets
LH/hCG receptor
Scientific explanation
Gs- steroidogenic agonism.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Receptor to physiology
Target to downstream effect: LH/hCG receptor
Mechanistically Relevant Repurposed & Adjunctive Applications
Hypogonadism / ovulation induction (labelled products)
EstablishedMechanistic rationale
Established hormone for labelled fertility and selected hypogonadism protocols.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| LHCGR | Agonism | Steroidogenesis / ovulation | Established mechanism |
In Plain Language
hCG is the pregnancy hormone that also looks like LH. In men it can tell the testes to make testosterone; in women it can mimic the ovulation LH signal.
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.